Editas Medicine, Inc. (EDIT): Price and Financial Metrics


Editas Medicine, Inc. (EDIT): $38.02

-0.93 (-2.39%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EDIT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 504

in industry

EDIT POWR Grades


  • Value is the dimension where EDIT ranks best; there it ranks ahead of 55.77% of US stocks.
  • EDIT's strongest trending metric is Growth; it's been moving down over the last 51 weeks.
  • EDIT ranks lowest in Sentiment; there it ranks in the 1st percentile.

EDIT Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for EDIT is 0.13 -- better than merely 13.42% of US stocks.
  • With a price/sales ratio of 32.77, Editas Medicine Inc has a higher such ratio than 92.95% of stocks in our set.
  • As for revenue growth, note that EDIT's revenue has grown 148.86% over the past 12 months; that beats the revenue growth of 95.28% of US companies in our set.
  • Stocks that are quantitatively similar to EDIT, based on their financial statements, market capitalization, and price volatility, are RARE, RGNX, SLDB, DRNA, and XLRN.
  • Visit EDIT's SEC page to see the company's official filings. To visit the company's web site, go to www.editasmedicine.com.

EDIT Valuation Summary

  • EDIT's price/sales ratio is 53.5; this is 1307.89% higher than that of the median Healthcare stock.
  • EDIT's price/earnings ratio has moved down 17.1 over the prior 68 months.
  • EDIT's price/earnings ratio has moved down 17.1 over the prior 68 months.

Below are key valuation metrics over time for EDIT.

Stock Date P/S P/B P/E EV/EBIT
EDIT 2021-08-31 53.5 7.1 -26.0 -24.1
EDIT 2021-08-30 52.0 6.9 -25.3 -23.4
EDIT 2021-08-27 55.1 7.3 -26.8 -24.9
EDIT 2021-08-26 53.7 7.1 -26.2 -24.2
EDIT 2021-08-25 55.2 7.3 -26.9 -24.9
EDIT 2021-08-24 54.4 7.2 -26.5 -24.6

EDIT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EDIT has a Quality Grade of D, ranking ahead of 13.09% of graded US stocks.
  • EDIT's asset turnover comes in at 0.12 -- ranking 251st of 681 Pharmaceutical Products stocks.
  • SMMT, BPMC, and VSTM are the stocks whose asset turnover ratios are most correlated with EDIT.

The table below shows EDIT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.120 1 -0.458
2021-03-31 0.140 1 -0.450
2020-12-31 0.158 1 -0.468
2020-09-30 0.164 1 -0.447
2020-06-30 0.065 1 -0.704
2020-03-31 0.057 1 -0.806

EDIT Price Target

For more insight on analysts targets of EDIT, see our EDIT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $50.75 Average Broker Recommendation 1.78 (Moderate Buy)

EDIT Stock Price Chart Interactive Chart >

Price chart for EDIT

EDIT Price/Volume Stats

Current price $38.02 52-week high $99.95
Prev. close $38.95 52-week low $27.12
Day low $37.86 Volume 955,900
Day high $39.48 Avg. volume 2,019,065
50-day MA $56.04 Dividend yield N/A
200-day MA $48.98 Market Cap 2.60B

Editas Medicine, Inc. (EDIT) Company Bio


Editas Medicine Inc. operates as a genome editing company. It focuses on translating its genome editing technology into a class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a range of diseases at the genetic level. Editas Medicine Inc. was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. The company was founded in 2013 and is based in Cambridge, Massachusetts.


EDIT Latest News Stream


Event/Time News Detail
Loading, please wait...

EDIT Latest Social Stream


Loading social stream, please wait...

View Full EDIT Social Stream

Latest EDIT News From Around the Web

Below are the latest news stories about Editas Medicine Inc that investors may wish to consider to help them evaluate EDIT as an investment opportunity.

4 Biotechs to Watch Amid Rising Prominence of Gene Therapies

Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, that have the potential to gain from their promising gene therapy pipeline candidates.

Yahoo | October 14, 2021

Editas (EDIT) Focuses on Developing Gene Drug for Eye Disease

Editas (EDIT) progresses well with the development of its lead candidate, EDIT-101, to treat LCA10, a rare genetic illness that causes blindness. Dependence on partners for revenues is a concern.

Yahoo | October 13, 2021

Editas Medicine to Present Preclinical Data on Novel Engineered iPSC Derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting

CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the Company will present preclinical data on its progress in the development of cell therapy medicines for the treatment of cancer at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting being held in Washington, D.C., and virtually, November 10-14, 2021. The Company will present a poster on its new method to drive high-level constitutive

Yahoo | October 7, 2021

3 Spooky Healthcare Stocks I Would Avoid in October

According to Yardeni Research, September has offered the worst average returns for the S&P 500 since 1928, at -1%. Jason Hawthorne (Brookdale Senior Living): The number of Americans at least 65 years old is set to more than double over the next four decades. Brookdale has been simplifying its business by selling assets over the last few years, but it still has several attributes that concern me.

Yahoo | October 7, 2021

Gene Editing Stocks Hyped Lately: What about Editas?

Gene editing stocks have been all the rage of late. Various companies utilizing CRISPR technology to edit the genomes of patients have made some intriguing recent breakthroughs. These breakthroughs, along with the growth potential said technologies could have for the healthcare sector generally, have made gene editing stocks among the top growth plays in the market right now. Growth investing guru Cathie Wood agrees. Among two of her core holdings in her genomics fund are Intellia Therapeutics (NTLA) and Editas Medicine (EDIT). Intellia is Wood's larger holding. It's also outperformed rival Editas. However, there's reason to like Editas right now.

Chris MacDonald on TipRanks | October 5, 2021

Read More 'EDIT' Stories Here

EDIT Price Returns

1-mo -37.67%
3-mo -10.31%
6-mo 11.27%
1-year 12.95%
3-year 28.62%
5-year 186.73%
YTD -45.77%
2020 136.78%
2019 30.15%
2018 -25.97%
2017 89.34%
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8459 seconds.